PATIENTS CARE ABOUT CURES, NOT CONFLICT OF INTEREST
More than a third of doctors who sit on review boards overseeing the integrity of clinical trials do not bother to disclose a financial stake in the outcome, a study in the New England Journal of Medicine has shown. However this does not shock cancer patients. In the same journal another study found that 80% were “not worried at all” if a doctor profited from a tested drug. In fact, most patients said that they opposed bans on such relationships. The author of the study said that this was quite understandable since participants in clinical trials “are very vulnerable, have a serious problem and want someone to care for it.”
Michael Cook edits BioEdge, a bioethics newsletter, and MercatorNet, an on-line magazine whose focus is human dignity. He writes from Sydney, Australia.
Latest posts by Michael Cook (see all)
- How long can you put off seeing the doctor because of lockdowns? - December 3, 2021
- House of Lords debates assisted suicide—again - October 28, 2021
- Spanish government tries to restrict conscientious objection - October 28, 2021
More Stories
A first in France: a trans mum and a trans dad
Trigger warning: if you are easily confused by gender pronouns, this story from France may cause heart palpitations. February 19...
Nigerian power couple convicted in London over organ trafficking plot
In May last year, a young Nigerian man stumbled into a police station into the English town of Staines, in...
Cease and desist: Dutch sperm donor who has fathered 550 children is being sued
A Dutch woman and a foundation for children of sperm donors are suing a Dutch man for fathering too many...
Should intractable mental illness make you eligible for euthanasia?
Canada is in the middle of a vigorous debate about whether incurable mental illness is grounds for Medical Assistance in...
Belgium to permit multiple gender ID changes
Belgium will permit people to change their gender identity as often as they want. The Minister of Justice, Vincent Van...
Nature’s foray into politics may have backfired
In the 2020 election, a swag of high-profile science journals, including Nature, Science, The Lancet, and the New England Journal...